ITGAM Gene

Overview

flowchart TD
    ITGAM["ITGAM"] -->|"activates"| Ms["Ms"]
    ITGAM["ITGAM"] -->|"activates"| Cancer["Cancer"]
    ITGAM["ITGAM"] -->|"activates"| Tumor["Tumor"]
    ITGAM["ITGAM"] -->|"activates"| Fibrosis["Fibrosis"]
    ITGAM["ITGAM"] -->|"regulates"| Als["Als"]
    ITGAM["ITGAM"] -->|"activates"| Ischemia["Ischemia"]
    ITGAM["ITGAM"] -->|"activates"| Myocardial_Infarction["Myocardial Infarction"]
    ITGAM["ITGAM"] -->|"activates"| Cardiac["Cardiac"]
    ITGAM["ITGAM"] -->|"activates"| Inflammation["Inflammation"]
    ITGAM["ITGAM"] -->|"associated with"| Alzheimer["Alzheimer"]
    ITGAM["ITGAM"] -->|"associated with"| Aging["Aging"]
    ITGAM["ITGAM"] -->|"associated with"| Senescence["Senescence"]
    ITGAM["ITGAM"] -->|"associated with"| Als["Als"]
    ITGAM["ITGAM"] -->|"expressed in"| ALS["ALS"]
    style ITGAM fill:#4fc3f7,stroke:#333,color:#000

Itgam Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

ITGAM encodes integrin alpha M (CD11b), the alpha chain of the heterodimeric receptor alphaMbeta2 (CR3/Mac-1) with ITGB2. In the CNS this receptor is central to myeloid adhesion, complement-opsonin recognition, phagocytosis, and inflammatory signal integration in microglia.^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}

Core Biology

CD11b/CD18 is a multifunctional immune receptor that binds complement fragment iC3b, ICAM-family ligands, fibrinogen, and damage-associated molecular patterns. In neurodegeneration-relevant contexts, ITGAM supports:

• Adhesion and migration of myeloid cells

• Recognition of complement-opsonized synapses and aggregates

• Phagocytosis and respiratory burst signaling

• Crosstalk with Toll-like and cytokine signaling pathways^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference3Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta22015 · Front Immunol · DOI 10.3389/fimmu.2015.00657Open reference}

Because complement system activation is prominent in AD, PD, and ALS tissue, ITGAM is a mechanistically important bridge between complement deposition and effector microglial responses.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference4Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · DOI 10.1126/science.aad8373Open reference}

Role in Alzheimer’s disease

In Alzheimer’s disease, CD11b-positive microglia accumulate near plaques and neuritic pathology. Complement tagging and CR3-dependent uptake can help clear cellular debris, yet persistent activation may also enhance synapse loss and inflammatory injury if not tightly regulated.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference4Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · DOI 10.1126/science.aad8373Open reference5The classical complement cascade mediates CNS synapse elimination2007 · Cell · DOI 10.1016/j.cell.2007.10.036Open reference}

This duality makes ITGAM relevant to therapeutic design: overly suppressing CR3 can impair clearance, while unchecked activation may amplify chronic neuroinflammation and circuit dysfunction.

Role in Parkinson’s disease

In Parkinson’s disease, CD11b upregulation is consistently reported in activated microglia within nigrostriatal regions.^{6Immune system responses in Parkinson's disease: early and dynamic2019 · Lancet Neurol · DOI 10.1016/S1474-4422(19Open reference} Engagement of ITGAM-dependent signaling alongside alpha-synuclein-triggered innate immune pathways contributes to cytokine release and oxidative stress pressure on dopaminergic neurons.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}0^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}1

Role in ALS and related disorders

In amyotrophic lateral sclerosis, CD11b-positive myeloid responses track with disease progression in spinal cord and motor pathways.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}2 Similar ITGAM-associated signatures are observed in other disorders where neuroinflammation and complement dysregulation are major pathogenic axes.

Pathway Context and Network Placement

ITGAM sits at the interface of immune recognition and tissue remodeling:

1. Injury or aggregate burden promotes complement activation and opsonization.

2. iC3b-coated targets are recognized by CR3 (ITGAM/ITGB2).

3. Cytoskeletal and kinase pathways drive engulfment and inflammatory transcription.

4. Net effect depends on disease stage, target type (debris vs synapse), and co-signaling via receptors such as TREM2.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}3^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}4^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}5

This connects ITGAM directly to complement-mediated-synapse-loss, innate-immune-signaling-ad, and selective-neuronal-vulnerability.

Therapeutic and Biomarker Implications

Potential translational strategies include:

• Tuning complement-CR3 signaling rather than complete pathway shutdown

• Combining CR3-axis modulation with anti-aggregate therapies

• Using tissue/imaging signatures of CD11b-high microglia as pharmacodynamic readouts in immune-modulating trials^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}6^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}7^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}8

Because ITGAM is broadly expressed across myeloid populations, CNS-targeted approaches should account for peripheral immune effects and stage-dependent biology.

Open Questions

• Which ITGAM signaling states are protective (clearance) versus pathogenic (synapse injury)?

• How does ITGAM interact with APOE-TREM2 programs across disease stages?

• Can precision modulation of CR3 improve outcomes without compromising host defense or repair?

Disease Associations

Top DisGeNET gene-disease associations for this gene are listed below. Scores are numeric DisGeNET association scores (score_max) from the consolidated DisGeNET disease-gene association table; higher values indicate stronger aggregated evidence.

Source: DisGeNET-derived consolidated disease-gene associations (dhimmel/disgenet, gene symbol ITGAM).

See Also

• Microglia — Resident immune cells of the CNS expressing ITGAM (CD11b)

• Neuroinflammation — Inflammatory processes in neurodegeneration

• Complement System — Immune pathway involving ITGAM

• CD11b Protein — Alternative name for ITGAM protein

• Multiple Sclerosis — Autoimmune disease with microglial involvement

• Alzheimer’s Disease — Neurodegenerative disease with neuroinflammation

External Links

• NCBI Gene: ITGAM

• UniProt: ITGAM (P05106)

• GeneCards: ITGAM

• HGNC: ITGAM

Overview

Itgam Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Itgam Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Genetics and Clinical Interpretation

Outside neurodegeneration, ITGAM coding variants are well studied in systemic autoimmune disease, showing that modest shifts in CR3 function can materially alter immune tone.^{2The good, the bad, and the opportunities of the complement system in neurodegenerative disease2020 · J Immunol · DOI 10.4049/jimmunol.1502069Open reference}9^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}0 For CNS applications, this supports a precision-medicine view: genotype, disease stage, and inflammatory milieu likely determine whether CR3-axis modulation is beneficial or detrimental.

In translational neurodegeneration studies, CD11b is best interpreted as part of a panel that includes complement activation markers, microglial state programs, and neuronal injury biomarkers.^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}1^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}2^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}3 This multi-marker approach is important because high CD11b signal can reflect effective debris clearance, maladaptive synapse stripping, or mixed states coexisting in the same tissue region.

Intervention Logic in AD and PD Programs

For Alzheimer’s disease, a plausible intervention strategy is staged modulation: preserve early CR3-dependent plaque compaction/clearance while limiting chronic complement-driven synaptic injury in later disease phases.^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}4^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}5

For Parkinson’s disease, ITGAM-targeted approaches may need to be paired with therapies that reduce alpha-synuclein burden and oxidative injury to avoid isolated immune suppression without substrate control.^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}6^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}7^{1Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein2000 · Crit Rev Immunol · PMID 10906929Open reference}8